Do skeletal-related events predict overall survival in men with metastatic castration-resistant prostate cancer?

Prostate Cancer and Prostatic Diseases

Volumn 19, Issue 4, 2016, Pages 380-384

  Howard, L E ^a,b   De Hoedt, A M ^b   Aronson, W J ^c,d   Kane, C J ^e   Amling, C L ^f   Cooperberg, M R ^g   Terris, M K ^h,i   Divers, C H ^j,k   Valderrama, A ^j   Freedland, S J ^b,k  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO HEALTH SYSTEM   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h VETERANS AFFAIRS MEDICAL CENTER   (United States)

ⁱ MEDICAL COLLEGE OF GEORGIA   (United States)

^j US Health Economics   (United States)

^k CEDARS SINAI MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AGE DISTRIBUTION; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE METASTASIS; BONE PAIN; CANCER MORTALITY; CANCER RADIOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; ETHNICITY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDIAN SURVIVAL TIME; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATECTOMY; SURVIVAL PREDICTION; VERY ELDERLY; BONE; BONE TUMOR; COHORT ANALYSIS; MORTALITY; PATHOLOGIC FRACTURE; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SECONDARY; SPINAL CORD COMPRESSION;

AGED; AGED, 80 AND OVER; BONE AND BONES; BONE NEOPLASMS; COHORT STUDIES; FRACTURES, SPONTANEOUS; HUMANS; MALE; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RISK FACTORS; SPINAL CORD COMPRESSION;

EID: 84977103915     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2016.26     Document Type: Article

References (21)

1. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012; 61: 1079-1092.
2. Sturge J, Caley MP, Waxman J. Bone metastasis in prostate cancer: emerging therapeutic strategies. Nat Rev Clin Oncol 2011; 8: 357-368.
3. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512.
4. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014; 371: 424-433.
5. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormonerefractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458-1468.
6. Smith MR, Coleman RE, Klotz L, Pittman K, Milecki P, Ng S et al. Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events. Ann Oncol 2015; 26: 368-374.
7. Logothetis CJ, Basch E, Molina A, Fizazi K, North SA, Chi KN et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castrationresistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol 2012; 13: 1210-1217.
8. Fizazi K, Scher HI, Miller K, Basch E, Sternberg CN, Cella D et al. Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. Lancet Oncol 2014; 15: 1147-1156.
9. Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369: 213-223.
10. Norgaard M, Jensen AO, Jacobsen JB, Cetin K, Fryzek JP, Sorensen HT. Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol 2010; 184: 162-167.
11. Sathiakumar N, Delzell E, Morrisey MA, Falkson C, Yong M, Chia V et al. Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999-2006. Prostate Cancer Prostatic Dis 2011; 14: 177-183.
12. Onukwugha E, Yong C, Mullins CD, Seal B, McNally D, Hussain A. Skeletal-related events and mortality among older men with advanced prostate cancer. J Geriatr Oncol 2014; 5: 281-289.
13. McDougall JA, Bansal A, Goulart BH, McCune JS, Karnopp A, Fedorenko C et al. The clinical and economic impacts of skeletal-related events among medicare enrollees with prostate cancer metastatic to bone. Oncologist 2016; 21: 320-326.
14. Moreira DM, Howard LE, Sourbeer KN, Amarasekara HS, Chow LC, Cockrell DC et al. Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 2015; 18: 333-337.
15. Scher HI, Morris MJ, Basch E, Heller G. End points and outcomes in castrationresistant prostate cancer: from clinical trials to clinical practice. J Clin Oncol 2011; 29: 3695-3704.
16. Hamilton RJ, Aronson WJ, Terris MK, Kane CJ, Presti JC Jr, Amling CL et al. Limitations of prostate specific antigen doubling time following biochemical recurrence after radical prostatectomy: results from the SEARCH database. J Urol 2008; 179: 1785-1790.
17. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005; 294: 433-439.
18. Aly A, Onukwugha E, Woods C, Mullins CD, Kwok Y, Qian Y et al. Measurement of skeletal related events in SEER-Medicare: a comparison of claims-based methods. BMC Med Res Methodol 2015; 15: 65.
19. Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377: 813-822.
20. James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2015; 387: 1163-1177.
21. Oudard S, Banu E, Medioni J, Scotte F, Banu A, Levy E et al. What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel? BJU Int 2009; 103: 1641-1646.